The Board of Joint stock company Grindeks informs that on 13 July, 2012, according to the authority given by the Meeting of Shareholders on 19 June, 2012, basing on the tender results and upon agreement with the Supervisory Council, it has appointed “Deloitte Audits Latvia” Ltd (certificate number 43) as auditor of the Annual Reports of Joint stock company Grindeks for the year 2012, determining the remuneration for the auditor for audit of the Annual Reports of Joint stock company Grindeks for the year 2012 in the amount of LVL 18,976 (eighteen thousand nine hundred seventy six lats), excluding taxes provided by the legislative acts.

About Grindeks

Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries.

Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently Grindeks produces 22 active pharmaceutical ingredients.

Products of the company are exported to 50 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany and the Netherlands. In 2010 The Ministry of Economics of Republic of Latvia and Investment and Development Agency of Latvia awarded Grindeks as the most export potential company of Latvia.
During the last years the company realized many considerable investment projects in purpose to increase production capacity and develop infrastructure and invested 32.7 million lats within five years.

JSC Grindeks shares are listed in the Official List of „Nasdaq OMX Riga”. Major shareholders of JSC Grindeks are Kirovs Lipmans – 33.29%, Anna Lipmane – 16.69%, “AB.LV Private Equity fund 2010” – 11.38%, “Skandinaviska Enskilda Banken” – 10.94%, “Swedbank” AS Clients Account – 8.28%.

Further information:

Jevgenija Briede-Birone
Deputy Manager of the Communications Department, JSC Grindeks
Ph: (+371) 67083247, (+371) 26304462
Fax: (+371) 67083505
E-mail: jevgenija.briede@grindeks.lv